Zoledronic acid + Placebo
Phase 2UNKNOWN 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Complex Regional Pain Syndromes
Conditions
Complex Regional Pain Syndromes
Trial Timeline
Dec 1, 2013 → Dec 1, 2016
NCT ID
NCT01788176About Zoledronic acid + Placebo
Zoledronic acid + Placebo is a phase 2 stage product being developed by Novartis for Complex Regional Pain Syndromes. The current trial status is unknown. This product is registered under clinical trial identifier NCT01788176. Target conditions include Complex Regional Pain Syndromes.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (12)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01788176 | Phase 2 | UNKNOWN |
| NCT01702415 | Approved | Withdrawn |
| NCT01166178 | Phase 3 | Terminated |
| NCT00844480 | Phase 2 | Terminated |
| NCT01016093 | Phase 2/3 | UNKNOWN |
| NCT00781261 | Phase 2 | UNKNOWN |
| NCT00799266 | Phase 3 | Completed |
| NCT00333229 | Approved | Terminated |
| NCT00320710 | Phase 3 | Completed |
| NCT00375505 | Phase 3 | Completed |
| NCT00145327 | Phase 3 | Completed |
| NCT00132808 | Phase 3 | Completed |
Competing Products
20 competing products in Complex Regional Pain Syndromes
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Zonisamide | Eisai | Phase 3 | 77 |
| Eslicarbazepine acetate + Eslicarbazepine acetate | Sumitomo Pharma | Phase 3 | 77 |
| Everolimus (RAD001) + Everolimus Placebo | Novartis | Phase 3 | 77 |
| RAD001 + Placebo | Novartis | Phase 2 | 52 |
| RAD001 + Placebo + Antiepileptic drug (1 to 3 only) + open label RAD001 (only used for post-extension phase) | Novartis | Phase 3 | 77 |
| everolimus | Novartis | Phase 3 | 77 |
| ranolazine | Gilead Sciences | Phase 2 | 51 |
| clarithromycin, rifabutin | Pfizer | Approved | 84 |
| Pregabalin + Pregabalin | Pfizer | Approved | 84 |
| Pregabalin | Pfizer | Pre-clinical | 22 |
| Azithromycin | Pfizer | Approved | 84 |
| Azithromycin + Rifabutin/rifampin | Pfizer | Approved | 84 |
| Stavudine | Bristol Myers Squibb | Phase 3 | 76 |
| Zidovudine + Didanosine | Bristol Myers Squibb | Phase 2 | 51 |
| Haemocomplettan® P + Human albumin (Placebo) | CSL | Phase 2/3 | 64 |
| BE1116 + FFP | CSL | Phase 3 | 76 |
| CSL730 + Placebo | CSL | Phase 1 | 32 |
| vigabatrin | Lundbeck | Approved | 82 |
| Sabril | Lundbeck | Approved | 82 |
| GWP42003-P | Jazz Pharmaceuticals | Phase 3 | 74 |